EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Silvio Danese 1
Kiyomi Komori 2
Rathi D. Ryan 2
Fabio Cataldi 2
Caroline A. Lee 2
Martina Goetsch 3
Britta Siegmund 4
1 IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
2 Arena Pharmaceuticals, a wholly-owned subsidiary of Pfizer Inc, New York, San Diego, United States
3 Arena Pharmaceuticals Development GmbH, a wholly-owned subsidiary of Pfizer Inc, New York, Zug, Switzerland
4 Charité - Universitätsmedizin Berlin, Berlin, Germany
Session
Clinical trials in IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]